European Neuropsychopharmacology最新文献

英文中文

“Much ado about nothing?” advocating for neuroscientific research in maternal perfectionism and perinatal mental health disorders

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.02.001

Chrishanthy Grace Jayarajah

引用次数: 0

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-08 DOI: 10.1016/j.euroneuro.2024.12.013

Eduard Vieta , Nahida Ahmed , Celso Arango , Anthony J. Cleare , Koen Demyttenaere , Markus Dold , Tetsuro Ito , Yerkebulan Kambarov , Stephanie Krüger , Pierre-Michel Llorca , Roger S. McIntyre , Gabriele Sani , Christian von Holt , Benoit Rive

Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects of esketamine nasal spray (NS) versus quetiapine extended release (XR) on functioning, work productivity and activity impairment. ESCAPE‑TRD (NCT04338321) was a 32-week randomised, open‑label, rater‑blinded, active‑controlled phase IIIb study comparing the efficacy and safety of esketamine NS versus quetiapine XR, both alongside an ongoing selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor (SSRI/SNRI), in patients with TRD. Patient functioning was assessed via the Sheehan Disability Scale (SDS; functional remission ≤6). Absenteeism, presenteeism, work productivity loss and activity impairment over time were assessed using the Work Productivity and Activity Impairment: Depression (WPAI:D) questionnaire. Results were cumulated over the entire study duration. Esketamine NS-treated patients (N = 336) experienced 43.2 % more weeks with functional remission versus quetiapine XR-treated patients (N = 340) over the 32-week study period (difference: 2.0 weeks [95 % CI: 0.7, 3.3]; p = 0.0023 [ANCOVA models]). Up to Week 32, esketamine NS-treated patients experienced an 11.9 % reduction in productivity loss due to absenteeism (difference: −1.1 weeks [95 % CI: −2.9, 0.7]; p = 0.2285) and a 14.2 % reduction in overall work productivity loss (difference: –2.3 weeks, 95 % CI: [–3.9, –0.7] p = 0.0045) versus quetiapine XR-treated patients, based on mixed models for repeated measures. Patients receiving esketamine NS experienced greater improvements in functioning and productivity over 32 weeks versus quetiapine XR. These improvements demonstrate the clinical and functional benefit of treatment with esketamine NS for patients with TRD.

{"title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study","authors":"Eduard Vieta , Nahida Ahmed , Celso Arango , Anthony J. Cleare , Koen Demyttenaere , Markus Dold , Tetsuro Ito , Yerkebulan Kambarov , Stephanie Krüger , Pierre-Michel Llorca , Roger S. McIntyre , Gabriele Sani , Christian von Holt , Benoit Rive","doi":"10.1016/j.euroneuro.2024.12.013","DOIUrl":"10.1016/j.euroneuro.2024.12.013","url":null,"abstract":"<div><div>Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects of esketamine nasal spray (NS) versus quetiapine extended release (XR) on functioning, work productivity and activity impairment. ESCAPE‑TRD (NCT04338321) was a 32-week randomised, open‑label, rater‑blinded, active‑controlled phase IIIb study comparing the efficacy and safety of esketamine NS versus quetiapine XR, both alongside an ongoing selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor (SSRI/SNRI), in patients with TRD. Patient functioning was assessed via the Sheehan Disability Scale (SDS; functional remission ≤6). Absenteeism, presenteeism, work productivity loss and activity impairment over time were assessed using the Work Productivity and Activity Impairment: Depression (WPAI:D) questionnaire. Results were cumulated over the entire study duration. Esketamine NS-treated patients (<em>N</em> = 336) experienced 43.2 % more weeks with functional remission versus quetiapine XR-treated patients (<em>N</em> = 340) over the 32-week study period (difference: 2.0 weeks [95 % CI: 0.7, 3.3]; <em>p</em> = 0.0023 [ANCOVA models]). Up to Week 32, esketamine NS-treated patients experienced an 11.9 % reduction in productivity loss due to absenteeism (difference: −1.1 weeks [95 % CI: −2.9, 0.7]; <em>p</em> = 0.2285) and a 14.2 % reduction in overall work productivity loss (difference: –2.3 weeks, 95 % CI: [–3.9, –0.7] <em>p</em> = 0.0045) versus quetiapine XR-treated patients, based on mixed models for repeated measures. Patients receiving esketamine NS experienced greater improvements in functioning and productivity over 32 weeks versus quetiapine XR. These improvements demonstrate the clinical and functional benefit of treatment with esketamine NS for patients with TRD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 29-39"},"PeriodicalIF":6.1,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia 精神分裂症患者的性别分层死亡率估计：对2,700,825名精神分裂症患者队列研究的系统回顾和荟萃分析。

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-01 DOI: 10.1016/j.euroneuro.2024.11.001

Marco Solmi , Giovanni Croatto , Nicholas Fabiano , Stanley Wong , Arnav Gupta , Michele Fornaro , Lynne Kolton Schneider , S. Christy Rohani-Montez , Leanne Fairley , Nathalie Smith , István Bitter , Philip Gorwood , Heidi Taipale , Jari Tiihonen , Samuele Cortese , Elena Dragioti , Ebba Du Rietz , Rene Ernst Nielsen , Joseph Firth , Paolo Fusar-Poli , Christoph U. Correll

The differential influence of sex on premature mortality in schizophrenia is unclear. This study assessed the differences in all-cause and specific cause mortality risks in people with schizophrenia compared to several control groups stratified by sex. We conducted a PRISMA 2020-compliant systematic review and random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) for people with schizophrenia, comparing by sex. We measured publication bias and conducted a quality assessment through the Newcastle-Ottawa scale. We meta-analyzed 43 studies reporting on 2,700,825 people with schizophrenia. Both males and females with schizophrenia had increased all-cause mortality vs. comparison groups (males, RR=2.62, 95%CI 2.35–2.92; females, RR=2.56, 95%CI 2.27–2.87), suicide (males, RR=9.02, 95%CI 5.96–13.67; females, RR=12.09, 95%CI 9.00–16.25), and natural cause mortality (males, RR=2.11, 95%CI 1.88–2.38; females, RR=2.14, 95%CI 1.93–2.38). No statistically significant differences in sex-dependent mortality risk emerged. There was an age-group-dependent increased mortality risk in females < 40 years vs. >/=40 years old (RR=4.23/2.17), and significantly higher risk of death due to neurological disorders (dementia) in males vs. females (RR=5.19/2.40). Increased mortality risks were often associated with specific modifiable risk factors. The increased mortality risk did not improve over time, calling for more studies to identify modifiable factors, and for better physical healthcare for males and females with schizophrenia.

性别对精神分裂症患者过早死亡的不同影响尚不清楚。本研究评估了精神分裂症患者与按性别分层的几个对照组相比，全因和特殊原因死亡率风险的差异。我们对评估精神分裂症患者死亡率相对风险（RR）的队列研究进行了一项符合PRISMA 2020标准的系统评价和随机效应荟萃分析，并按性别进行了比较。我们测量了发表偏倚，并通过纽卡斯尔-渥太华量表进行了质量评估。我们荟萃分析了43项涉及2,700,825名精神分裂症患者的研究。男性和女性精神分裂症患者的全因死亡率均高于对照组(男性，RR=2.62, 95%CI 2.35-2.92；女性，RR=2.56, 95%CI 2.27 ~ 2.87)，自杀(男性，RR=9.02, 95%CI 5.96 ~ 13.67；女性，RR=12.09, 95%CI 9.00-16.25)和自然原因死亡率(男性，RR=2.11, 95%CI 1.88-2.38；女性，RR=2.14, 95%CI 1.93 ~ 2.38)。性别依赖性死亡风险没有统计学上的显著差异。40岁以下的女性与40岁以下的女性相比死亡风险增加（RR=4.23/2.17），男性因神经系统疾病（痴呆）死亡的风险明显高于女性（RR=5.19/2.40）。死亡风险的增加往往与特定的可改变的危险因素有关。随着时间的推移，死亡风险的增加并没有改善，这需要更多的研究来确定可改变的因素，并为患有精神分裂症的男性和女性提供更好的身体保健。

{"title":"Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia","authors":"Marco Solmi , Giovanni Croatto , Nicholas Fabiano , Stanley Wong , Arnav Gupta , Michele Fornaro , Lynne Kolton Schneider , S. Christy Rohani-Montez , Leanne Fairley , Nathalie Smith , István Bitter , Philip Gorwood , Heidi Taipale , Jari Tiihonen , Samuele Cortese , Elena Dragioti , Ebba Du Rietz , Rene Ernst Nielsen , Joseph Firth , Paolo Fusar-Poli , Christoph U. Correll","doi":"10.1016/j.euroneuro.2024.11.001","DOIUrl":"10.1016/j.euroneuro.2024.11.001","url":null,"abstract":"<div><div>The differential influence of sex on premature mortality in schizophrenia is unclear. This study assessed the differences in all-cause and specific cause mortality risks in people with schizophrenia compared to several control groups stratified by sex. We conducted a PRISMA 2020-compliant systematic review and random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) for people with schizophrenia, comparing by sex. We measured publication bias and conducted a quality assessment through the Newcastle-Ottawa scale. We meta-analyzed 43 studies reporting on 2,700,825 people with schizophrenia. Both males and females with schizophrenia had increased all-cause mortality vs. comparison groups (males, RR=2.62, 95%CI 2.35–2.92; females, RR=2.56, 95%CI 2.27–2.87), suicide (males, RR=9.02, 95%CI 5.96–13.67; females, RR=12.09, 95%CI 9.00–16.25), and natural cause mortality (males, RR=2.11, 95%CI 1.88–2.38; females, RR=2.14, 95%CI 1.93–2.38). No statistically significant differences in sex-dependent mortality risk emerged. There was an age-group-dependent increased mortality risk in females < 40 years vs. >/=40 years old (RR=4.23/2.17), and significantly higher risk of death due to neurological disorders (dementia) in males vs. females (RR=5.19/2.40). Increased mortality risks were often associated with specific modifiable risk factors. The increased mortality risk did not improve over time, calling for more studies to identify modifiable factors, and for better physical healthcare for males and females with schizophrenia.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 56-66"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Classical psychedelics in therapy: Essential psychotherapy or minimal support?

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-01 DOI: 10.1016/j.euroneuro.2025.01.004

Gitte M Knudsen

引用次数: 0

Dilemmas in psychedelic medicine: From ethics to regulation and equity 迷幻药的困境：从伦理到监管和公平。

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-01 DOI: 10.1016/j.euroneuro.2024.11.003

Albino J. Oliveira-Maia , Carolina Seybert

引用次数: 0

Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression 检查共病性创伤后应激障碍对氯胺酮在治疗难治性抑郁症中的实际有效性的影响。

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-01 DOI: 10.1016/j.euroneuro.2024.11.008

Danica E. Johnson , Nelson B. Rodrigues , Sydney Weisz , Noah Chisamore , Erica S. Kaczmarek , David C.J. Chen-Li , Zoe Doyle , J Don Richardson , Rodrigo B. Mansur , Roger S. McIntyre , Joshua D. Rosenblat

Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients from the Canadian Rapid Treatment Center of Excellence to compare the effectiveness of four ketamine infusions (0.5–0.75 mg/kg) in reducing symptoms of depression and PTSD in TRD patients with and without comorbid PTSD.

A repeated-measures linear mixed model was used to evaluate the impact of comorbid PTSD on ketamine's antidepressant effectiveness, measured by the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Paired samples t-tests were used to assess changes in PTSD symptoms, measured by the PTSD Checklist for DSM-5 (PCL-5). We found a significant main effect of time on QIDS-SR16 scores, F(4, 209.32) = 36.67, p < 0.001, but no significant group-by-time interaction (p = 0.895), suggesting that comorbid PTSD did not impact the antidepressant effectiveness of ketamine. Significant improvements in PTSD symptoms were observed in overall PCL-5 scores, t(66) = 6.66, p < 0.001, and across all PCL-5 symptom clusters with moderate to large effect sizes.

In a real-world sample of TRD patients, ketamine was effective in reducing symptoms of depression and PTSD, regardless of PTSD comorbidity. These findings highlight ketamine's potential as a novel intervention for a patient population that is frequently non-responders to conventional treatments. Future randomized controlled trials should explore mediating factors of improvement and long-term effects.

抑郁症合并创伤后应激障碍（PTSD）与更严重的症状和对传统治疗的反应降低有关。尽管氯胺酮有望作为治疗难治性抑郁症（TRD）的速效抗抑郁药，但其对合并PTSD患者的有效性仍有待进一步研究。因此，我们对来自加拿大卓越快速治疗中心的134例患者进行了回顾性分析，比较四种氯胺酮输注（0.5-0.75 mg/kg）在减轻合并和不合并PTSD的TRD患者抑郁和PTSD症状方面的效果。采用重复测量线性混合模型评估共病PTSD对氯胺酮抗抑郁效果的影响，采用抑郁症状自我报告快速量表（QIDS-SR16）测量。配对样本t检验用于评估PTSD症状的变化，由DSM-5的PTSD检查表（PCL-5）测量。我们发现时间对QIDS-SR16评分有显著的主影响，F(4,209.32) = 36.67, p < 0.001，但各组间无显著的时间交互作用（p = 0.895），提示共病性PTSD不影响氯胺酮的抗抑郁效果。在总体PCL-5评分中观察到创伤后应激障碍症状的显著改善，t(66) = 6.66, p < 0.001，并且在所有PCL-5症状群中具有中等到较大的效应量。在真实世界的TRD患者样本中，氯胺酮可以有效地减轻抑郁和PTSD的症状，而不考虑PTSD的合并症。这些发现突出了氯胺酮作为一种新的干预措施的潜力，用于对常规治疗经常无反应的患者群体。未来的随机对照试验应探索改善和长期影响的中介因素。

{"title":"Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression","authors":"Danica E. Johnson , Nelson B. Rodrigues , Sydney Weisz , Noah Chisamore , Erica S. Kaczmarek , David C.J. Chen-Li , Zoe Doyle , J Don Richardson , Rodrigo B. Mansur , Roger S. McIntyre , Joshua D. Rosenblat","doi":"10.1016/j.euroneuro.2024.11.008","DOIUrl":"10.1016/j.euroneuro.2024.11.008","url":null,"abstract":"<div><div>Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients from the Canadian Rapid Treatment Center of Excellence to compare the effectiveness of four ketamine infusions (0.5–0.75 mg/kg) in reducing symptoms of depression and PTSD in TRD patients with and without comorbid PTSD.</div><div>A repeated-measures linear mixed model was used to evaluate the impact of comorbid PTSD on ketamine's antidepressant effectiveness, measured by the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Paired samples <em>t</em>-tests were used to assess changes in PTSD symptoms, measured by the PTSD Checklist for DSM-5 (PCL-5). We found a significant main effect of time on QIDS-SR16 scores, F(4, 209.32) = 36.67, <em>p</em> < 0.001, but no significant group-by-time interaction (<em>p</em> = 0.895), suggesting that comorbid PTSD did not impact the antidepressant effectiveness of ketamine. Significant improvements in PTSD symptoms were observed in overall PCL-5 scores, t(66) = 6.66, <em>p</em> < 0.001, and across all PCL-5 symptom clusters with moderate to large effect sizes.</div><div>In a real-world sample of TRD patients, ketamine was effective in reducing symptoms of depression and PTSD, regardless of PTSD comorbidity. These findings highlight ketamine's potential as a novel intervention for a patient population that is frequently non-responders to conventional treatments. Future randomized controlled trials should explore mediating factors of improvement and long-term effects.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 69-77"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential effects of Xanomeline-trospium chloride on positive and negative symptoms in Schizophrenia: The role of dose

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-01-31 DOI: 10.1016/j.euroneuro.2025.01.005

Tzu-Yen Hung , Yo-Chia Hsu , Yang-Chieh Brian Chen , Chih-Wei Hsu

引用次数: 0

Lack of antidepressant-like effect of imipramine, fluoxetine and ketamine in the forced swim test in mice: How much standardization does a positive control require?

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-01-30 DOI: 10.1016/j.euroneuro.2024.12.012

Marcela Verginia de Medeiros , Eduardo Antonio Rosa , Gabriela Vissintainer , Cilene Lino de Oliveira , Bruno Jacson Martynhak

引用次数: 0

Disease continuum centered on Parkinson's disease

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-01-29 DOI: 10.1016/j.euroneuro.2025.01.002

Ming Zheng

Parkinson’s disease (PD), once viewed as a neurodegenerative disorder, is now increasingly recognized as part of a broader disease continuum, intricately linked to comorbidities across various organ systems. This study provides a snapshot of the disease continuum centered on PD, using a disease-wide association study (DWAS) involving 392,423 individuals—including 4,235 PD cases. This DWAS identifies disease clusters of PD comorbidities across the musculoskeletal, circulatory, digestive, and respiratory systems. Moreover, comorbidities were classified based on their temporal relationship to PD diagnosis: pre-PD comorbidities, such as hypertension and autoimmune disorders, may act as risk factors of PD onset, while post-PD comorbidities, including Alzheimer’s disease and renal disorders, highlight the systemic consequences of PD progression. These findings emphasize the critical need for early detection and intervention to manage comorbidities and potentially delay PD onset. Furthermore, this study advocates for integrated diagnostic and therapeutic strategies targeting shared risk factors, advancing a precision-medicine approach to improve patient care and long-term management of PD.

{"title":"Disease continuum centered on Parkinson's disease","authors":"Ming Zheng","doi":"10.1016/j.euroneuro.2025.01.002","DOIUrl":"10.1016/j.euroneuro.2025.01.002","url":null,"abstract":"<div><div>Parkinson’s disease (PD), once viewed as a neurodegenerative disorder, is now increasingly recognized as part of a broader disease continuum, intricately linked to comorbidities across various organ systems. This study provides a snapshot of the disease continuum centered on PD, using a disease-wide association study (DWAS) involving 392,423 individuals—including 4,235 PD cases. This DWAS identifies disease clusters of PD comorbidities across the musculoskeletal, circulatory, digestive, and respiratory systems. Moreover, comorbidities were classified based on their temporal relationship to PD diagnosis: pre-PD comorbidities, such as hypertension and autoimmune disorders, may act as risk factors of PD onset, while post-PD comorbidities, including Alzheimer’s disease and renal disorders, highlight the systemic consequences of PD progression. These findings emphasize the critical need for early detection and intervention to manage comorbidities and potentially delay PD onset. Furthermore, this study advocates for integrated diagnostic and therapeutic strategies targeting shared risk factors, advancing a precision-medicine approach to improve patient care and long-term management of PD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 19-21"},"PeriodicalIF":6.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): An open-label pilot study

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-01-28 DOI: 10.1016/j.euroneuro.2025.01.003

Bonnie L. Quigley , Adem T. Can , Megan Dutton , Cyrana C. Gallay , Grace Forsyth , Monique Jones , Fiona Randall , Trish Wilson , Jim Lagopoulos , Daniel F. Hermens

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Neuropsychopharmacology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀